Okazaki Jason A 4

What Happened

• Jason A. Okazaki, CEO, President and Director of Assembly Biosciences (ASMB), received a grant of 50,750 restricted stock units (RSUs) on March 29, 2026. The RSUs were granted at $0.00 (no cash paid) and the reported acquisition value is $0. This is an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: March 29, 2026 (Form filed June 5, 2026).
• Price: $0.00 per share; total reported value $0.
• Vesting/issuance: RSUs were granted on March 29, 2026 but became issuable upon stockholder approval of a Plan Amendment on June 4, 2026. They vest in four approximately equal installments assuming continuous service: 3/29/2027, 3/29/2028, 3/29/2029 and 3/29/2030.
• Grant size note: Footnote states these RSUs represent 35% of the reporting person's annual equity grant approved on March 29, 2026.
• Additional note (F2): filing mentions 688 shares acquired under the company’s ESPP on May 14, 2026.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Timeliness: The Form 4 was filed on June 5, 2026 reporting a March 29, 2026 grant — later than the usual two-business-day Form 4 filing window.

Context

• RSUs are restricted units that convert to shares if the vesting conditions are met; this grant does not involve immediate cash proceeds or an exercise. Because issuance was contingent on a shareholder-approved Plan Amendment, the units only became issuable after that approval (6/4/2026). Awards like this are routine compensation for executives and are different from open-market purchases, which some investors view as a stronger bullish signal.